$NBIO A third payment of USD $2,500,000 will be re
Post# of 38450
(Total Views: 221)
Posted On: 02/23/2022 9:36:31 AM
$NBIO
Quote:
A third payment of USD $2,500,000 will be received by Nascent upon approval from the FDA to conduct a Phase 2 clinical trial of Pritumumab.
(0)
(0)